Alkermes - 2/13

Entry	Author	Date	Location
Editor’s Picks: Xconomy Boston’s Top 20 Stories of the First Quarter	Gregory T. Huang	03/31/11	Boston
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News	Erin Kutz	03/04/11	Boston
Amylin, Lilly, Alkermes Diabetes Drug Doesn’t Match Rival in Head-to-Head Study	Ryan McBride	03/03/11	Boston
Alkermes Sees Chance to Reinvent Vivitrol For Fighting Drug Addiction, Not Just Alcoholism	Luke Timmerman	02/18/11	Boston
Adriana Jenkins, Boston Biotech PR Maven, Dies from Breast Cancer at 41	Luke Timmerman	02/10/11	Boston
Rib-X Wrappes Up $20M, Oxford Closes $66M on Sixth Fund, Ocular Adds $6M, & More Boston-Area Life Sciences News	Erin Kutz	01/14/11	Boston
$12.7M Blows in for Wind Power Holdings, Epizyme Forges Alliance with GlaxoSmithKline, & Many More Boston-Area Deals	Rebecca Zacks	01/12/11	Boston
Alkermes Finds New Home For Inhaled Drug-Delivery Tech with Civitas Spinout	Ryan McBride	01/10/11	Boston
Lilly Funds Cerulean, Genzyme Sells Diagnostics Unit, Roche Ends RNAi Program, & More Boston-Area Life Sciences News	Erin Kutz	11/19/10	Boston
Alkermes CEO Leans on Internal Pipeline as Bydureon Hangs Out in the Penalty Box	Ryan McBride	11/15/10	Boston
ATyr Pharma Pockets $23M to Create New Class of Protein Drugs, and New Targets	Luke Timmerman	10/26/10	San Diego
Alkermes Drops on FDA Rejection, Glaxo’s SR One Backs Dicerna, Biogen Reworks Genentech Alliance, & More Boston-Are Life Sciences News	Erin Kutz	10/22/10	Boston
Amylin, Alkermes Shares Crash on Surprise FDA Smackdown	Luke Timmerman	10/20/10	San Diego
Amylin, Alkermes Once-Weekly Diabetes Drug Fails to Win FDA Approval	Luke Timmerman	10/19/10	San Diego
Alkermes Drug Approved for Opioid Addiction, Genzyme Faces Shareholder Lawsuits, NinePoint Gets $33M, & More Boston-Area Life Sciences News	Erin Kutz	10/15/10	Boston
Amylin, Alkermes Eagerly Await FDA Verdict (Again) For Once-Weekly Diabetes Drug	Luke Timmerman	10/15/10	San Diego
Alkermes Gets Drug Approval	Ryan McBride	10/12/10	Boston
Acceleron Weans Itself Off VC, Continues its Roll with Pharma Partner Dollars	Ryan McBride	09/28/10	Boston
Alkermes Wins FDA Panel Nod	Luke Timmerman	09/16/10	Boston
Acceleron Snags $498M Deal With Shire to Develop Muscular Dystrophy Drugs	Luke Timmerman	09/09/10	Boston
Third Rock Invests in Ablexis, Acceleron Grabs $8.4M, Alnylam Chief Joins Agios Board, & More Boston-Area Life Sciences News	Erin Kutz	06/25/10	Boston
$8M for Acceleron	Erin Kutz	06/22/10	Boston
Metcalfe Says Gore Is Back for Another Bubble, Fitton Likens Raising Angel Funding to Dating, Xconomy CEO Sings New England’s Praises (Literally), and More XSITE 2010 Highlights	Erin Kutz	06/21/10	Boston
Biogen CEO Retires, Genzyme Board Nominates Amgen Vet and Strikes Deal with Icahn, Xconomy Spotlights Life Sciences XSITE Speakers, & More Boston-Area Life Sciences News	Erin Kutz	06/11/10	Boston
XSITE’s Biotech Gurus to Cover the State of New England Biotech, the Return of Platforms	Luke Timmerman	06/07/10	Boston
Is it Time for the FDA to Chime in on Drug Company Tweets?	Sylvia Pagán Westphal	05/26/10	National
Free Copy of Jeff Bussgang’s ‘Mastering the VC Game’ for the Next 25 Purchasers of XSITE 2010 Tickets	Robert Buderi	05/24/10	Boston
Sequenom Restarts Down Syndrome Test, Cytori Upbeat About Cardiac Study, Pathway Genomics Mass Markets Genome Tests, & More San Diego Life Sciences News	Denise Gellene	05/13/10	San Diego
Icahn Blasts Genzyme Manufacturing, Glaxo Halts “Red Wine” Drug Trial, Ariad Gets $69M from Merck, & More Boston-Area Life Sciences News	Erin Kutz	05/07/10	Boston
Amylin, Alkermes Get New FDA Date	Luke Timmerman	05/06/10	National
Page 2 of 5	« previous page · next page »

Entry

Author

Date

Location

Editor’s Picks: Xconomy Boston’s Top 20 Stories of the First Quarter

03/31/11

RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News

Erin Kutz

03/04/11

Boston

Amylin, Lilly, Alkermes Diabetes Drug Doesn’t Match Rival in Head-to-Head Study

Ryan McBride